DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0163449 A1 Wempe (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2009/0163449 A1 Wempe (43) Pub US 200901 63449A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0163449 A1 Wempe (43) Pub. Date: Jun. 25, 2009 (54) SULFO-POLYMER POWDER AND (22) Filed: Oct. 31, 2008 SULFO-POLYMER POWDER BLENDS WITH O O CARRIERS AND/OR ADDITIVES Related U.S. Application Data (60) Provisional application No. 61/015,365, filed on Dec. (75) Inventor: Michael Fitzpatrick Wempe, 20, 2007. Kingsport, TN (US) Publication Classification Correspondence Address: (51) Int. Cl. BRETTL NELSON A613/60 (2006.01) EASTMLAN CHEMICAL COMPANY A6II 47/34 (2006.01) 1OO NORTHEASTMAN ROAD (52) U.S. Cl. ...................................... 514/159; 514/772.3 KINGSPORT, TN37660-5075 (US) (57) ABSTRACT (73) Assignee: Eastman Chemical Company, Sulfo-polyester powders and sulfo-polyester blend powders, Kingsport, TN (US) the incorporation of carriers and/or actives, and methods of making the powders as well as dispersions employing these (21) Appl. No.: 12/262,986 powders. AQ38S (Left) and AQ38P (Right) Comparison & & Patent Application Publication Jun. 25, 2009 Sheet 2 of 3 US 2009/O163449 A1 Figure 2 Kojic Acid Hydroquinone Vitamin12 E TPGS-1000 Salicyclic Acid Glycolic Acid Lidocaine CO2H CO2H HO N1N N OH r Patent Application Publication Jun. 25, 2009 Sheet 3 of 3 US 2009/O163449 A1 Figure 3A g 125 v AQ55+ traconazole 100 I AUC 612 it 170 ng himl 75 ; i CMC + traconazole 3 50 v, AUCo24. 115 it 59 ng himl 25 O Figure 3B 250 A AG.55 traConazole 200 AUC-24 1429 it 755 ng himl 32 150 SSO XSS 100 O Ces5 50 US 2009/01 63449 A1 Jun. 25, 2009 SULFO-POLYMER POWDER AND 0014. Yet another embodiment concerns a cosmetic com SULFO-POLYMER POWDER BLENDS WITH position, comprising the compositions described above and a CARRIERS AND/OR ADDITIVES cosmetically acceptable carrier. 0015. Another embodiment concerns a pharmaceutical or CROSS-REFERENCE TO RELATED agricultural composition, comprising the compositions APPLICATIONS described above and a pharmaceutically or agriculturally 0001. This application claims priority to U.S. Provisional acceptable carrier. Application Ser. No. 61/015.365, filed Dec. 20, 2007 the disclosure of which is incorporated herein by reference in its entirety. BRIEF DESCRIPTION OF THE DRAWINGS BACKGROUND OF THE INVENTION 0016 FIG. 1 shows a side-by-side comparison of a sul 0002 Sulfo-polyesters (such as Eastman AQ polymers) fopolyester polymer and the corresponding powder. are high molecular weight amorphous polyesters commonly 0017 FIG. 2 shows the chemical structures for various dispersed directly in water without the need to incorporate compound examples incorporated with Sulfopolyester poly organic co-solvents, Surfactants, or amines. Sulfo-polyesters mer powders. differ chiefly by their chemical makeup (i.e. they are com 0018 FIG. 3A shows the oral dose blood concentration posed of 5-sodiosulfoisophthalic acid (5-SSIPA) and various time data for itraconazole for two dosing groups; and combinations of other materials, for example: terephthalic 0019 FIG. 3B shows the oral dose blood concentration acid (TPA), isophthalic acid (IPA), ethylene glycol (EG), time data for hydroxy-itraconazole for two dosing groups. diethylene glycol (DEG), 1,4-cyclohexanedimethanol (CHDM), and/or 1,4-cyclohexanedicarboxylic acid (1,4- DETAILED DESCRIPTION CHDA). The temperature where a glassy polymer becomes rubbery on heating, and vice versa upon cooling, is known as 0020. The present invention concerns sulfo-polyester the glass transition temperature (T). Hence, the various powders and Sulfo-polyester blend powders, the incorpora sulfo-polyester polymers have different average T values. tion of carriers and/or actives, and methods of making the 0003 Sulfopolyesters are solid to semi-solid polymers powders as well as dispersions employing these powders. and require warm to hot water with Sufficient mixing time to 0021 Sulfo-polyester powder(s) and sulfo-polyester pow prepare concentrated dispersions. Moreover, different sulfo der blend(s) with and without carriers and/or actives are pre polyester polymer dispersions may possess trace volatile pared by dispersing said Sulfo-polyester powder(s) and Sulfo components and potentially cause odor. Therefore methods polyester powder blend(s) in a solvent or solvent mixture that improve dissolution and/or lower volatile content may be (e.g., water, water and alcohol mixtures, etc) at various tem advantageous. peratures. The exact solvent, or solvent mixture, and tempera BRIEF SUMMARY OF THE INVENTION tures used will be a function of the application end usage 0004. The present invention addresses solutions to issues and/or required dispersion percentage. End uses of said Sulfo previously described and enables the preparation of sul polyester powder(s) and sulfo-polyester powder blend(s) fopolyester polymer powders and/or blends containing carri include Sun care/skin care applications (i.e. creams, lotions ers (e.g. Surfactants) and/or actives, and dispersions of Sul and sprays), perfume applications (i.e. flavors, fragrances, fopolyester or sulfopolyester blends with and without carriers essential oils, etc), hairstyling applications (i.e. hair gel and and/or actives, having reduced odor, using water and/or sol hairspray), color makeup and hairstyling applications, drug vent mixtures with Sufficient mixing. delivery applications, and adhesive removal Such as re-pulp 0005. An embodiment of the present invention concerns a ing of paper and plastic and glass recycling. composition comprising at least one Sulfonated copolyester 0022. As used throughout this application, the term “pow and at least one active agent, wherein said composition is a der' shall mean particles in the range of 0.5-5000 uM. The powder. Science and technology of small particles is known as “micro 0006 Yet another embodiment concerns a method of metrics' (for a general review, see Physical Pharmacy and increasing the bioavailability of an active agent comprising Pharmaceutical Sciences Fifth Edition by Patrick J. Sinko, administering the composition described in the previous Lippincott Williams & Wilkins, 2006, ISBN: 0-7817-5027 paragraph to a subject (i.e. an organism). X). The unit commonly used to describe particle size is the 0007 Another embodiment concerns a method for pro micrometer (Lm). In general, optical microscopy may be used ducing a sulfonated copolyester powder containing an active to measure particle-sizes of about 0.2 to about 100 um; how agent comprising: ever, other techniques may also be used to determine approxi 0008 a) dispersing at least one sulfonated coployester and mate size ranges, such as sedimentation, coulter counter, at least one active agent in a solvent, or solvent mixture, to airpermeability, sieving, etc. form a dispersion; and 0023 Techniques such as sieving, according to methods of 0009 b) drying said dispersion to form a powder. the U.S. Pharmacopeia, may be used to determine powder 0010. Another embodiment concerns a method for pro fineness, or other properties of the corresponding powders ducing a sulfonated copolyester powder containing an active and/or powder blends; for example, particle size and size agent comprising: distribution (i.e. average particle size, particle-size distribu 0011 a) dispersing at least one sulfonated copolyester in a tion (frequency distribution curve), number and weight dis Solvent to form a dispersion; and tributions, particle number), particle Volume, particle shape 0012 b) drying said dispersion to form a powder; and and Surface area, pore size, porosity, particle density, bulki 0013 c) mixing (grinding, milling, and the like) said Sul ness, flow properties, etc. Because many powders have a fonated copolyester powder with at least one active agent. tendency to contain a non-symmetric particle size distribu US 2009/01 63449 A1 Jun. 25, 2009 tion, it is common to plot the log-normal distribution; com ture. Various methods to evaluate dissolution are well known; monly, this method results in a linear relationship. Subse for a general review, see Physical Pharmacy and Pharmaceu quently, the "geometric mean diameter” (d; the particle size tical Sciences Fifth Edition by Patrick J. Sinko, Lippincott equivalent to 50% on the probability scale) may be obtained Willams & Wilkins, 2006, ISBN: 0-7817-5027-X. Therefore, from plotting the logarithm of the particle size against the one should readily appreciate that the application end usage cumulative percent frequency on a probability Scale. There and/or required dispersion percentage would dictate the exact fore, as used throughout this application, powders shall be Solvent, or solvent mixture, and temperatures used to prepare classified into different particle size ranges, such as: dispersions from the powders. For example, a temperature of extremely fine powders (i.e. dusty powders: 0.5-50 um), about 70° C. to about 10°C., about 50° C. to about 15° C., or fine powders (50-100 um), 'coarse powders (100-1000 about 35° C. to about 18° C. maybe used. Typically, the um), and granular powders (1000-5000 um). mixtures are stirred at room temperature, or elevated tempera 0024. In an embodiment of the present invention, the com ture, until the sulfo-polyester powder or sulfo-polyesterpow positions are generally prepared by techniques such as lyo der blend becomes dispersed which can be a time period of philization, spray-drying, jet milling, spray freeze-drying, about 12 h to about 1 min, of about 6 h to about 5 min, or of fluidized-bed spray coating, Supercritical fluid methods, etc. about 2 h to about 15 min. The different techniques are based on different mechanisms 0030. As used throughout this application, the term “lipo of droplet/particle formation and/or 15 drying (for a general philic compounds' shall mean compounds having Solubility review, see Lyophilization of Biopharmaceuticals' edited by in water that is in the “sparingly soluble' range, or lower. Henry R. Costantino and Michael J. Pikal, AAPS Press, 2004, Persons of ordinary skill in the art will understand that, for ISBN: 0-9711767-6-0). compounds that are “sparingly soluble in water, the quantity 0025.
Load more

Recommended publications
  • COMBINED LIST of Particularly Hazardous Substances
    COMBINED LIST of Particularly Hazardous Substances revised 2/4/2021 IARC list 1 are Carcinogenic to humans list compiled by Hector Acuna, UCSB IARC list Group 2A Probably carcinogenic to humans IARC list Group 2B Possibly carcinogenic to humans If any of the chemicals listed below are used in your research then complete a Standard Operating Procedure (SOP) for the product as described in the Chemical Hygiene Plan. Prop 65 known to cause cancer or reproductive toxicity Material(s) not on the list does not preclude one from completing an SOP. Other extremely toxic chemicals KNOWN Carcinogens from National Toxicology Program (NTP) or other high hazards will require the development of an SOP. Red= added in 2020 or status change Reasonably Anticipated NTP EPA Haz list COMBINED LIST of Particularly Hazardous Substances CAS Source from where the material is listed. 6,9-Methano-2,4,3-benzodioxathiepin, 6,7,8,9,10,10- hexachloro-1,5,5a,6,9,9a-hexahydro-, 3-oxide Acutely Toxic Methanimidamide, N,N-dimethyl-N'-[2-methyl-4-[[(methylamino)carbonyl]oxy]phenyl]- Acutely Toxic 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) Prop 65 KNOWN Carcinogens NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) IARC list Group 2A Reasonably Anticipated NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) Prop 65 1-(o-Chlorophenyl)thiourea Acutely Toxic 1,1,1,2-Tetrachloroethane IARC list Group 2B 1,1,2,2-Tetrachloroethane Prop 65 IARC list Group 2B 1,1-Dichloro-2,2-bis(p -chloropheny)ethylene (DDE) Prop 65 1,1-Dichloroethane
    [Show full text]
  • Commission Implementing Regulation (EU)
    21.3.2013 EN Official Journal of the European Union L 80/1 II (Non-legislative acts) REGULATIONS COMMISSION IMPLEMENTING REGULATION (EU) No 230/2013 of 14 March 2013 on the withdrawal from the market of certain feed additives belonging to the group of flavouring and appetising substances (Text with EEA relevance) THE EUROPEAN COMMISSION, submitted before that deadline for the only animal category for which those feed additives had been auth­ orised pursuant to Directive 70/524/EEC. Having regard to the Treaty on the Functioning of the European Union, (4) For transparency purposes, feed additives for which no applications for authorisation were submitted within the Having regard to Regulation (EC) No 1831/2003 of the period specified in Article 10(2) of Regulation (EC) No European Parliament and of the Council of 22 September 1831/2003 were listed in a separate part of the 2003 on additives for use in animal nutrition ( 1 ), and in Community Register of Feed Additives. particular Article 10(5) thereof, (5) Those feed additives should therefore be withdrawn from Whereas: the market as far as their use as flavouring and appetising substances is concerned, except for animal species and categories of animal species for which applications for (1) Regulation (EC) No 1831/2003 provides for the auth­ authorisation have been submitted. This measure does orisation of additives for use in animal nutrition and not interfere with the use of some of the abovemen­ for the grounds and procedures for granting such auth­ tioned additives according to other animal species or orisation. Article 10 of that Regulation provides for the categories of animal species or to other functional re-evaluation of additives authorised pursuant to Council groups for which they may be allowed.
    [Show full text]
  • Ranvet's Filybol
    Ranvet's Filybol Ranvet Chemwatch Hazard Alert Code: 2 Chemwatch: 4787-83 Issue Date: 08/02/2016 Version No: 5.1.1.1 Print Date: 10/28/2016 Safety Data Sheet according to WHS and ADG requirements S.GHS.AUS.EN SECTION 1 IDENTIFICATION OF THE SUBSTANCE / MIXTURE AND OF THE COMPANY / UNDERTAKING Product Identifier Product name Ranvet's Filybol Chemical Name peanut oil Synonyms Not Available Other means of Not Available identification Relevant identified uses of the substance or mixture and uses advised against Relevant identified Non-virilising anabolic combination for fillies, mares, colts and stallions. uses Details of the supplier of the safety data sheet Registered company Ranvet name Address 10-12 Green Street Banksmeadow NSW 2019 Australia Telephone +61 2 9666 1744 Fax +61 2 9666 1755 Website https://www.ranvet.com.au/other_msds.htm Email [email protected] Emergency telephone number Association / Not Available Organisation Emergency telephone +61 425 061 584 numbers Other emergency Not Available telephone numbers SECTION 2 HAZARDS IDENTIFICATION Classification of the substance or mixture Poisons Schedule S4 Carcinogenicity Category 2, Reproductive Toxicity Category 2, Acute Aquatic Hazard Category 2, Chronic Aquatic Hazard Classification [1] Category 2 1. Classified by Chemwatch; 2. Classification drawn from HSIS ; 3. Classification drawn from EC Directive 1272/2008 - Annex Legend: VI Label elements GHS label elements SIGNAL WORD WARNING Continued... Chemwatch: 4787-83 Page 2 of 10 Issue Date: 08/02/2016 Version No: 5.1.1.1 Ranvet's Filybol Print Date: 10/28/2016 Hazard statement(s) H351 Suspected of causing cancer. H361 Suspected of damaging fertility or the unborn child.
    [Show full text]
  • Test Items for Licensing Examination Krok 1 PHARMACY
    MINISTRY OF PUBLIC HEALTH OF UKRAINE Department of human resources policy, education and science Testing Board Student ID Last name Variant ________________ Test items for licensing examination Krok 1 PHARMACY (російськомовний варіант) General Instruction Every one of these numbered questions or unfinished statements in this chapter corresponds to answers or statements endings. Choose the answer (finished statements) that fits best and fill in the circle with the corresponding Latin letter on the answer sheet. Authors of items: Abramov A.V., Aleksandrova K.V., Andronov D.Yu., Bilyk O.V., Blinder O.O., Bobyr V.V., Bobrovska O.A., Bohatyriova O.V., Bodnarchuk O.V., Boieva S.S., Bolokhovska T.O., Bondarenko Yu.I., Bratenko M.K., Buchko O.V., Cherneha H.V., Davydova N.V., Deriuhina L.I., Didenko N.O., Dmytriv A.M., Doroshkevych I.O., Dutka N.M., Dynnyk K.V., Filipova L.O., Havryliuk I.M., Herhel T.M., Hlushkova O.M., Hozhdzinsky S.M., Hrekova T.A., Hrechana O.V., Hruzevsky O.A., Hudyvok Ya.S., Hurmak I.S., Ivanets L.M., Ivanov Ye.I., Kartashova T.V., Kava T.V., Kazakova V.V., Kazmirchuk H.V., Kernychna I.Z., Khlus K.M., Khmelnykova L.I., Klebansky Ye.O., Klopotsky H.A., Klymniuk S.I., Kobylinska L.I., Koldunov V.V., Kolesnyk V.P., Kolesnikova T.O., Komlevoy O.M., Kononenko N.M., Kornijevsky Yu.Y., Kremenska L.V., Krushynska T.Yu., Kryzhanovska A.V., Kryshtal M.V., Kukurychkin Ye.R., Kuznietsova N.L., Kuzmina A.V., Lisnycha A.M., Lychko V.H., Makats Ye.F., Maly V.V., Matvijenko A.H., Menchuk K.M., Minarchenko V.M., Mikheiev A.O., Mishchenko
    [Show full text]
  • 2020 Veterinary and Agricultural Sciences
    Ukrainian Journal of 2020 Veterinary and Agricultural Sciences http://ujvas.com.ua Stepan Gzhytskyi National University of Veterinary Medicine and Biotechnologies Lviv Volume 3 review article UDC 619:618.14:618.19-002:636 doi: 10.32718/ujvas3-2.01 Number 2 Emergency contraception using progestin drugs in domestic cats A. Vasetska Luhansk National Agrarian University, Slobozanska Str., 68, Starobilsk, 92703, Ukraine Article info Abstract Received 16.03.2020 Received in revised form Today, in conditions of strict quarantine, when it is not always possible to carry out surgery in cats, some methods 20.04.2020 Accepted 21.04.2020 of emergency drug contraception can be used. Over the years, many contraceptive medications have been devel- oped for companion animals, but many secondary adverse effects have limited their use. However, in all species, Correspondence author the secondary adverse effects of progesterone-type drugs limit their use and vary depending on when treatment is Anastasiia Vasetska Tel.: +38-066-591-49-56 given in relationship to the stage of the estrous cycle. An ideal non-surgical sterilant would be safe, effective, E-mail: [email protected] permanent, administered as a single injection and capable of being manufactured inexpensively. Contraceptives are used for cats, as a method of renewable fertility over time for breeding animals, as a method of suppressing 2020 Vasetska A. This is an open- access article distributed under the sexual function for animals at risk for surgery, and to prevent over populations in stray cats. The use of non- terms of the Creative Commons surgical, safe and effective methods of suppression of sexual function in cats eliminates traumatization, anesthesia Attribution License, which permits and complicated postoperative period in animals, which in some cases are impossible in the state of health, etc.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Detection of Estrogen Receptor Endocrine Disruptor Potency of Commonly Used Organochlorine Pesticides Using the LUMI-CELL ER Bioassay
    DEVELOPMENTAL AND REPRODUCTIVE TOXICITY Detection of Estrogen Receptor Endocrine Disruptor Potency of Commonly Used Organochlorine Pesticides Using The LUMI-CELL ER Bioassay John D. Gordon1, Andrew C: Chu1, Michael D. Chu2, Michael S. Denison3, George C. Clark1 1Xenobiotic Detection Systems, Inc., 1601 E. Geer St., Suite S, Durham, NC 27704, USA 2Alta Analytical Perspectives, 2714 Exchange Drive, Wilmington, NC 28405, USA 3Dept. of Environmental Toxicology, Meyer Hall, Univ. of California, Davis; Davis, CA 95616 USA Introduction Organochlorine pesticides are found in many ecosystems worldwide as result of agricultural and industrial activities and exist as complex mixtures. The use of these organochlorine pesticides has resulted in the contamination of lakes and streams, and eventually the animal and human food chain. Many of these pesticides, such as pp ’-DDT, pp ’-DDE, Kepone, Vinclozolin, and Methoxychlor (a substitute for the banned DDT), have been described as putative estrogenic endocrine disruptors, and act by mimicking endogenous estrogen 1-3 . Estrogenic compounds can have a significant detrimental effect on the endocrine and reproductive systems of both human and other animal populations 4 . Previous studies have shown a strong association between several EDCs (17p-Estradiol, DES, Zeralanol, Zeralenone, Coumestrol, Genistein, Biochanin A, Diadzein, Naringenin, Tamoxifin) and estrogenic activity via uterotropic assay, cell height, gland number, increased lactoferrin, and a transcriptional activity assay using BG1Luc4E2 cells4 . Some other examples of the effects of these EDCs are: decreased reproductive success and feminization of males in several wildlife species; increased hypospadias along with reductions in sperm counts in men; increase in the incidence of human breast and prostate cancers; and endometriosis 3-5 .
    [Show full text]
  • Meta-Analysis of Benzodiazepine Use in the Treatment of Insomnia
    Meta-analysis of benzodiazepine use in the treatment of insomnia Review Anne M. Holbrook, Renée Crowther, Ann Lotter, Chiachen Cheng, Derek King Synthèse Abstract From the Centre for Evaluation of Medicines, Objective: To systematically review the benefits and risks associated with the use St. Joseph’s Hospital of benzodiazepines to treat insomnia in adults. and McMaster University, Data sources: MEDLINE and the Cochrane Controlled Trials Registry were Hamilton, Ont. searched for English-language articles published from 1966 to December 1998 that described randomized controlled trials of benzodiazepines for the treatment This article has been peer reviewed. of insomnia. Key words included “benzodiazepines” (exploded), “randomized controlled trial” and “insomnia.” Bibliographies of relevant articles were re- CMAJ 2000;162(2):225-33 viewed for additional studies and manufacturers of benzodiazepines were asked to submit additional randomized controlled trial reports not in the literature. ß An overview of the diagnosis and management of insomnia in clinical Study selection: Articles were considered for the meta-analysis if they were ran- practice appears on page 216. domized controlled trials involving patients with insomnia and compared a ben- zodiazepine with placebo or another active agent. Of the 89 trials originally identified, 45 met our criteria, representing a total of 2672 patients. January 25, 2000 Data extraction: Data were extracted regarding the participants, the setting, details Table of Contents of the intervention, the outcomes (including adverse effects) and the method- ologic quality of the studies. Data synthesis: The meta-analyses of sleep records indicated that, when compared with placebo, benzodiazepines decreased sleep latency by 4.2 minutes (non- significant; 95% confidence interval [CI] –0.7 to 9.2) and significantly increased total sleep duration by 61.8 minutes (95% CI 37.4 to 86.2).
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • Oral Magnesium Gly Magnesium Glycerophosphate Ceroph
    pat hways Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate Evidence summary Published: 29 January 2013 nice.org.uk/guidance/esuom4 Key points from the evidence The content of this evidence summary was up-to-date in January 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Magnesium glycerophosphate is a magnesium salt that is available as a tablet, capsule, liquid solution or liquid suspension for oral use. The British national formulary (BNF) states that oral magnesium glycerophosphate is a suitable preparation to prevent recurrence of symptomatic hypomagnesaemia in people who have already been treated for this condition. This evidence summary looks at the use of oral magnesium glycerophosphate in patients who have previously been treated with an intravenous infusion of magnesium. Oral magnesium glycerophosphate does not have UK marketing authorisation for this or any other indication, and therefore it is an unlicensed medicine in the UK. No published clinical trials comparing the efficacy of oral magnesium glycerophosphate with placebo or any form of active treatment for preventing recurrent hypomagnesaemia after treatment with intravenous magnesium were identified. The only videncee found was from 3 case reports describing the use of oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia in adults after intravenous treatment. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 17 Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4) Two of the 3 case reports concerned patients who had short bowel syndrome due to surgical resection.
    [Show full text]
  • 56 Subpart F—Flavoring Agents and Related Substances
    § 172.510 21 CFR Ch. I (4–1–12 Edition) needed to produce its intended effect (a) They are used in the minimum but not in excess of 13 parts per million quantity required to produce their in- calculated as anhydrous sodium ferro- tended physical or technical effect and cyanide. in accordance with all the principles of [42 FR 14491, Mar. 15, 1977, as amended at 58 good manufacturing practice. FR 17098, Apr. 1, 1993] (b) In the appropriate forms (plant parts, fluid and solid extracts, con- Subpart F—Flavoring Agents and centrates, absolutes, oils, gums, bal- Related Substances sams, resins, oleoresins, waxes, and dis- tillates) they consist of one or more of § 172.510 Natural flavoring substances the following, used alone or in com- and natural substances used in con- bination with flavoring substances and junction with flavors. adjuvants generally recognized as safe Natural flavoring substances and in food, previously sanctioned for such natural adjuvants may be safely used use, or regulated in any section of this in food in accordance with the fol- part. lowing conditions. Common name Scientific name Limitations Aloe ................................................................ Aloe perryi Baker, A. barbadensis Mill., A. ferox Mill., and hybrids of this sp. with A. africana Mill. and A. spicata Baker. Althea root and flowers .................................. Althea officinalis L. Amyris (West Indian sandalwood) ................. Amyris balsamifera L. Angola weed .................................................. Roccella fuciformis
    [Show full text]
  • Effects of Brotizolam, a New Thieno-Triazolo-Diazepine Derivative, on the Central Nervous System
    In the present study, its actions on the central nervous system were investigated. Effects of Brotizolam, a New Thieno-Triazolo-Diazepine Derivative, on the Central Nervous System Kenjiro KIMISHIMA, Kyoko TANABE, Yukako KINOSHITA, Kooji TOKUYOSHI, Daisuke HOURI and Tatsuo KOBAYASHI Department of Pharmacology, Tottori University School of Medicine, Yonago 683, Japan Accepted August 24, 1984 Abstract-The effects of brotizolam, a new thieno-triazolo-diazepine derivative, on the central nervous system were analyzed in mice, rats and rabbits. Diazepam, estazolam and triazolam were used as control drugs. Brotizolam inhibited spon taneous motor activities; performances in the rotarod test, staircase test, and maximal electroshock seizure test; and pentetrazol or bemegride-induced convulsion. Moreover, catalepsy inducing action and potentiating effect on sleep elicited by pentobarbital or ethanol were observed. Following intraperitoneal or oral admin istration of brotizolam to rabbits with chronically implanted electrodes , the electro encephalographic profile in spontaneous EEG was characterized by slow waves with high amplitudes in the neocortex. The arousal responses by stimulation of the midbrain reticular formation and posterior hypothalamus were slightly inhibited, but the recruiting responses induced by stimulation of the diffuse thalamic projecting system were not inhibited, and seizure discharges induced by stimulation of the dorsal hippocampus were inhibited markedly. When motor activities and pente trazol-induced convulsions were observed as indices of tolerance for brotizolam, tolerance was not developed by repeated administration of brotizolam up to 14 days. These results suggested that brotizolam, a new thieno-triazolo-diazepine derivative, is judged to be a safer and stronger sleep inducer than diazepam and estazolam . Since the pioneering paper by Randall et et al.
    [Show full text]